AMD

The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation for potential treatment of dry AMD, glaucoma, and neurodegenerative eye diseases.

The trial is expected to close randomization in early December 2024.

Key findings from the data include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.

A new classification system helps patients reach informed decisions.

The study is now expected to be fully enrolled with all 300 patients randomized by the end of 2024.

Related macular dystrophies (MDs) include Sorsby’s fundus dystrophy, Doyne honeycomb macular dystrophy, and autosomal dominant radial drusen.

Iris freckles are the most common melanocytic iris lesions, and UV sunlight is a well-known promoter of melanogenesis. Another study reported a higher rate of iris freckles in patients with UV-associated skin cancer.

The study looked at bevemipretide, which targets the inner mitochondrial membrane where it reversibly binds to cardiolipin.

By identifying progressive GA earlier, primary eye care providers can make timely referrals and save patients’ visual function.

Understanding the latest innovative technologies.

Comanagement is a key component for treatment of disease.

The new smart glasses utilize artificial intelligence to visually assist those with age-related macular degeneration and other retinal disorders causing vision loss.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.

The 2-year Phase III data demonstrates Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

The company also submitted a marketing authorization application with the European Medicines Agency.

Notal Vision’s device was given to 15 patients to track changes in their neovascular age-related macular degeneration for the study.

Apellis will seek re-examination from the CHMP following the opinion, according to a news release.

The company expects enrollment of the GAZE phase 1, open-label clinical trial, to begin in the second half of 2024.

Respecting the clinical importance of the pachychoroid spectrum is vital when analyzing OCT scans.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Researchers examined data of more than 200,000 people, 121,523 of which had no history of AMD.

The biotechnology company is developing the first protein-based artificial retina for patients with retinitis pigmentosa and age-related macular degeneration.

The COAST and ShORe trials have a total of 1984 patients enrolled for the treatment of wet age-related macular degeneration.

The study evaluated the effects of long-term, low-dose aspirin administration in over 3000 older adults.

Aflibercept-jbvf and aflibercept-yszy are the first interchangeable biosimilars to aflibercept 2 mg that have been approved in the US.

The SCANLY Home OCT device allows physicians to monitor patients’ wet age-related macular degeneration in between visits through a health cloud portal.

The clinical-stage biopharmaceutical company has enrolled 15 participants in its study to assess the safety and tolerability of ACT107 in 3 dose strengths.

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.